Reinventing phage therapy: are the parts greater than the sum?
- 1 December 2006
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 24 (12) , 1508-1511
- https://doi.org/10.1038/nbt1206-1508
Abstract
Although whole phage continue to generate interest as an alternative to antibiotics, focus is shifting to the use of purified phage components as antibacterial agents.Keywords
This publication has 42 references indexed in Scilit:
- Pharmacodynamics of non-replicating viruses, bacteriocins and lysinsProceedings Of The Royal Society B-Biological Sciences, 2006
- Application of Bacteriophages To Control Intestinal Escherichia coli O157:H7 Levels in RuminantsApplied and Environmental Microbiology, 2006
- PlyC: A multimeric bacteriophage lysinProceedings of the National Academy of Sciences, 2006
- Targeting Antibacterial Agents by Using Drug-Carrying Filamentous BacteriophagesAntimicrobial Agents and Chemotherapy, 2006
- PlyPH, a Bacteriolytic Enzyme with a Broad pH Range of Activity and Lytic Action against Bacillus anthracisJournal of Bacteriology, 2006
- Therapeutic Effects of Bacteriophage Cpl-1 Lysin against Streptococcus pneumoniae Endocarditis in RatsAntimicrobial Agents and Chemotherapy, 2005
- Viruses in the seaNature, 2005
- Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis modelPublished by Elsevier ,2005
- Are viruses driving microbial diversification and diversity?Environmental Microbiology, 2003
- The Pneumococcal Cell Wall Degrading Enzymes: A Modular Design to Create New Lysins?Microbial Drug Resistance, 1997